Its four approved medicines treat cystic fibrosis (CF), and one approved therapy ... This growth was attributed to its ex-Humira platform, a drug collection in the company’s pharmaceutical ...

This is despite the ongoing decline of long-time top-seller Humira (adalimumab), which ... and Vertex’s combination therapy for cystic fibrosis Trikafta (elexacaftor plus ivacaftor plus tezacaftor).

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

A scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, was among a trio who received this year’s Nobel Prize in Chemistry.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

High shipping and storage costs for importers of nitrogen fertilizer limit the competition CF faces in North American markets from outside regions with low natural gas costs.